AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AIM ImmunoTech Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.16−0.01 (-2.97%)
Close on Oct 19, 2026
- Market cap
- $2.79M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.4043 (−93.65%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
AIM ImmunoTech Inc. saw revenue fall 21.5% to $95.00K over the twelve months to Jun 30, 2026.
Revenue
$95.00K
-21.5% vs. a year earlier
Operating income
-$11.14M
TTM Q2 2026
EPS, diluted
-$8.62
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.79M
- P/E ratio
- –
- Price to sales
- 29.39
- Price to book
- 0.36
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $95.00K
- Net income
- -$14.27M
- EPS, diluted
- -$8.62
- Book value per share
- $0.45
- Diluted shares
- 17M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$95.00K-21.5% YoY
Gross profit
–
Operating income
-$11.14M
Net income
-$14.27M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months